Vertex’s Strategic Acquisition of Alpine Immune Sciences Signals Major Immunology Push
04.09.2025 - 06:54:04 | boerse-global.deAt the recent Wells Fargo Healthcare Conference, Vertex Pharmaceuticals CEO Reshma Kewalramani underscored the profound strategic importance of the company’s multi-billion dollar acquisition of Alpine Immune Sciences. This move represents a significant commitment to expanding Vertex’s immunology portfolio.
Finalized in the second quarter of 2024 after being announced in April of the same year, the transaction saw Vertex paying $65 per share, culminating in a total deal value of approximately $4.9 billion. Following the successful completion of the tender offer, Alpine Immune Sciences shares were delisted. The centerpiece of this acquisition is the promising drug candidate Povetacicept (formerly ALPN-303), a dual BAFF/APRIL antagonist. Clinical data has been compelling; in Phase 1b/2a studies, the treatment demonstrated a 64.1% reduction in Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos.
